Meeting
2014 ASCO Annual Meeting
NCI 8628: A randomized phase II study of ziv-aflibercept (Z) and high-dose interleukin-2 (HD IL-2) or HD IL-2 alone for inoperable stage III or IV melanoma—Efficacy and biomarker study.
Authors
Madeeha Ashraf
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Madeeha Ashraf , John M. Kirkwood , Marc S. Ernstoff , Hussein Abdul-Hassan Tawbi , Paul Henry Frankel , Nora Ruel , Kari Lynn Kendra , Thomas Olencki , Nikhil I. Khushalani , Theodore F. Logan , Kim Allyson Margolin , Alice P. Chen , Ahmad A. Tarhini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01258855
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS9120)
DOI
10.1200/jco.2014.32.15_suppl.tps9120
Abstract #
TPS9120
Poster Bd #
315A
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
First Author: Howard Kaufman
Poster
2014 ASCO Annual Meeting
A randomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM).
First Author: Rahima Jamal
Poster
2012 ASCO Annual Meeting
A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607).
First Author: Kevin Kalinsky
Poster
2012 ASCO Annual Meeting
A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.
First Author: Joyce Leta Steinberg